MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced a late-breaker presentation at the 2020 Multidisciplinary Head and Neck Cancers Symposium, which is taking place February 27-29, 2020, in Scottsdale, Ariz. The presentation includes final data from the two-year tumor outcomes follow up of patients with head and neck cancer treated with Galera’s lead product candidate, avasopasem manganese (GC4419), for severe oral mucositis (SOM) in a Phase 2b clinical trial.
Details of the presentation are as follows:
Presentation Number: LBA 2
Title: Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer
Session: Oral Abstract Session
Date/Time: Friday, February 28, 2020, 10:45 a.m. – 12:15 p.m. MST
Presenter: Carryn Anderson, M.D., Radiation Oncologist, University of Iowa Hospitals and Clinics
The 2020 Multidisciplinary Head and Neck Cancers Symposium brings the head and neck cancer community together to provide the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation. The meeting is cosponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Head and Neck Society (AHNS) and the Society for Immunotherapy of Cancer (SITC). For more information, visit https://www.headandnecksymposium.org/.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem manganese is being studied in the Phase 3 ROMAN trial for its ability to reduce the incidence, severity and duration of radiation-induced SOM in patients with locally advanced head and neck cancer being treated with radiotherapy, its lead indication, and in the Phase 2a trial for its ability to reduce the incidence of radiation-induced esophagitis in patients with lung cancer. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem manganese for the reduction of SOM induced by radiotherapy. Galera is developing a second product candidate, GC4711, which successfully completed a Phase 1 trial in healthy volunteers. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
Chiara Russo
Solebury Trout
617-221-9197
crusso@soleburytrout.com
Media Contact:
Heather Anderson
6 Degrees
919-827-5539
handerson@6degreespr.com
